Oral vitamin K (phytonadione and menaquinone-4) is associated with increased bone mineral density and reduced fracture incidence of up to 80% for hip fractures, according to a meta-analysis. Pooling the results of seven trials with fracture outcomes, researchers calculated an odds ratio favoring menaquinone of 0.40 (95% CI; 0.25–0.65) for vertebral fractures, 0.23 (95% CI; 0.12–0.47) for hip fractures, and 0.19 (95% CI; 0.11–0.35) for all nonvertebral fractures.
Oral vitamin K (phytonadione and menaquinone-4) is associated with increased bone mineral density and reduced fracture incidence of up to 80% for hip fractures, according to a meta-analysis. Pooling the results of seven trials with fracture outcomes, researchers calculated an odds ratio favoring menaquinone of 0.40 (95% CI; 0.25–0.65) for vertebral fractures, 0.23 (95% CI; 0.12–0.47) for hip fractures, and 0.19 (95% CI; 0.11–0.35) for all nonvertebral fractures.
But the authors of the review caution that the included studies were not designed to show a fracture effect, and such a dramatic effect-much larger than with treatments such as bisphosphonates-could be due to chance, the fact that all the studies with fracture outcomes were performed in Japan, and may be explained by some dietary or other lifestyle factor, or to some other unidentified factor.
Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:1256-1261.
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More